October 30, 2017 – By Peter Erickson
Analysts expect Jounce Therapeutics Inc (NASDAQ:JNCE) to report $-0.25 EPS on November, 8.After having $-0.11 EPS previously, Jounce Therapeutics Inc’s badysts see 127.27% EPS growth. It closed at $13.94 lastly. It is down 0.00% since October 30, 2016 and is . It has underperformed by 16.70% the S&P500.
Among 11 badysts covering Sanmina-SCI Corporation (NASDAQ:SANM), 4 have Buy rating, 0 Sell and 7 Hold. Therefore 36% are positive. Sanmina-SCI Corporation had 24 badyst reports since July 21, 2015 according to SRatingsIntel. On Wednesday, November 2 the stock rating was maintained by Needham with “Buy”. The firm has “Hold” rating by Zacks given on Tuesday, September 22. The firm has “Buy” rating given on Tuesday, January 31 by Needham. On Wednesday, November 4 the stock rating was maintained by Argus Research with “Buy”. Cross Research downgraded the shares of SANM in report on Monday, October 31 to “Hold” rating. The stock of Sanmina Corp (NASDAQ:SANM) earned “Hold” rating by Craig Hallum on Tuesday, July 26. RBC Capital Markets maintained Sanmina Corp (NASDAQ:SANM) rating on Thursday, August 31. RBC Capital Markets has “Hold” rating and $40.0 target. The firm earned “Hold” rating on Thursday, October 12 by RBC Capital Markets. Bank of America maintained the stock with “Buy” rating in Thursday, June 15 report. Goldman Sachs downgraded the stock to “Neutral” rating in Monday, August 3 report. See Sanmina Corp (NASDAQ:SANM) latest ratings:
12/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $40.0 Maintain
03/10/2017 Broker: Needham Rating: Buy New Target: $45.0 Maintain
31/08/2017 Broker: RBC Capital Markets Rating: Hold New Target: $40.0 Maintain
30/08/2017 Broker: Needham Rating: Buy New Target: $45.0 Maintain
25/07/2017 Broker: RBC Capital Markets Rating: Hold New Target: $40.0000
15/06/2017 Broker: Bank of America Rating: Buy New Target: $48 Maintain
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The company has market cap of $448.79 million. The Firm is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. It has a 6394.5 P/E ratio. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.29, from 1.24 in 2017Q1. It is negative, as 32 investors sold Sanmina Corp shares while 91 reduced holdings. 31 funds opened positions while 86 raised stakes. 69.46 million shares or 1.12% less from 70.25 million shares in 2017Q1 were reported. Thomson Horstmann Bryant invested in 6,600 shares. Brandywine Glob Inv Mngmt Ltd Liability Corp accumulated 0.09% or 355,501 shares. Connable Office invested in 0.07% or 7,812 shares. Meritage Portfolio Mngmt has invested 0.55% in Sanmina Corp (NASDAQ:SANM). Affinity Advisors Ltd Co invested in 0.03% or 6,196 shares. Capstone Asset stated it has 0.02% of its portfolio in Sanmina Corp (NASDAQ:SANM). Comml Bank Of Montreal Can, a Ontario – Canada-based fund reported 94,742 shares. Sadoff Investment Mngmt Ltd Limited Liability Company invested in 3.18% or 880,212 shares. Zpr Investment owns 32,795 shares. Foundry Ptnrs Ltd Liability Com owns 478,386 shares for 0.75% of their portfolio. Bessemer Gp Incorporated holds 60,800 shares or 0.01% of its portfolio. State Teachers Retirement Systems owns 72,323 shares. Fuller Thaler Asset Mngmt Inc reported 48,100 shares or 0.02% of all its holdings. 268,050 were reported by Bridgeway Capital Management. Pnc Fincl Services Group Inc Incorporated has 0.01% invested in Sanmina Corp (NASDAQ:SANM).
It closed at $39.05 lastly. It is down 44.39% since October 30, 2016 and is uptrending. It has outperformed by 27.69% the S&P500.
By Peter Erickson
Echostar Corporation-Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and badysts’ ratings with our FREE daily email newsletter.